Xofigo

Xofigo (Radium Ra 223 Dichloride) is an injectable radiopharmaceutical used for targeted treatment of bone metastases in certain cancers. This alpha-emitting therapy helps manage symptoms and slow disease progression. Suitable for patients with symptomatic bone metastases from prostate cancer.

Xofigo is primarily used to treat bone metastases in patients with advanced prostate cancer that has spread to the bones. It works by targeting areas of increased bone activity, such as metastatic sites, with radiation. This therapy is designed to relieve bone pain and reduce complications from bone metastases. Patients often ask, 'what is Xofigo used for' in the context of managing prostate cancer symptoms.

Xofigo is administered via intravenous injection and works by emitting alpha particles that target cancer cells in the bones. Patients may experience relief from bone pain as the treatment helps slow the progression of bone metastases. Some individuals notice improved mobility and reduced need for pain medications over time.

Xofigo should only be handled and administered by healthcare professionals trained in radiopharmaceutical use. Patients receiving Xofigo may need to take precautions to minimize radiation exposure to others, such as limiting close contact with pregnant women or young children. Blood counts should be monitored regularly during treatment.

Xofigo may interact with other systemic cancer therapies, including chemotherapy or hormone treatments, though specific interactions vary by patient. Patients should inform their healthcare provider about all medications, supplements, or radiation therapies they are receiving. Bone-modifying agents, such as bisphosphonates, may be used alongside Xofigo but require careful coordination.